Table 2.
Shepard's amalgamation of criteria for proof of human teratogenicity (Source: shepard, 1994 [51]) applied to SSRIs.
Criterion | Fulfillment by SSRIs |
---|---|
(1) Proven exposure to agent at critical time(s) in prenatal development. | No |
| |
(2) Consistent findings by two or more epidemiologic studies of high quality: | |
(a) Control of confounding factors | |
(b) Sufficient numbers | |
(c) Exclusion of positive or negative bias factors | No |
(d) Prospective studies, if possible | |
(e) Relative risk of six or more (?) | |
| |
(3) Careful delineation of the clinical cases. A specific defect or syndrome, if present, is very helpful | No |
| |
(4) Rare environmental exposure associated with rare defect | Not applicable |
| |
(5) Teratogenicity in experimental animals | No |
| |
(6) The association should make biological sense | No |
| |
(7) Proof in an experimental system that the agent acts in an unaltered state | Evidence of placental transfer |
Note: items (1), (2), and (3) or (1), (3), and (4) are essential criteria. Items (5), (6), and (7) are helpful but not essential.